Solstice Neurosciences

What Solstice Neurosciences does

Solstice Neurosciences, operating commercially as US WorldMeds (legal entity USWM, LLC), is a private specialty biopharmaceutical company founded in 2003. The company develops, licenses, manufactures, and markets pharmaceutical products targeted at patients with challenging conditions and unmet medical needs, with a stated therapeutic focus on hematology and oncology. Headquartered in Louisville, Kentucky (with a firmographic address in South San Francisco), the company employs 51-100 people and operates as a registered trademark holder under the USWM, LLC corporate structure.

The company's core activity centers on bringing unique specialty pharmaceutical products to market through internal development, in-licensing, and clinical research partnerships. Its R&D efforts are concentrated in rare disease research, with clinical trial and grant-based collaborations supporting pipeline advancement. The company's therapeutic portfolio addresses conditions where existing treatment options are limited, differentiating it from generic or commoditized pharmaceutical manufacturers. The firm maintains a clinical-stage infrastructure for developing and commercializing therapies in narrowly defined therapeutic areas rather than broad primary care indications.

Commercially, Solstice/US WorldMeds generates revenue through one-time license arrangements and specialty pharmaceutical product sales distributed directly to healthcare providers and patients through standard pharmaceutical distribution channels. The company has raised approximately $93 million in disclosed venture capital across two rounds (2005 and 2006), led by Highland Capital Partners with participation from Investor Growth Capital, Morgan Stanley Venture Partners, Oxford Bioscience Partners, and Thomas, McNerney & Partners. Its go-to-market relies on specialty pharma distribution rather than mass-market channels, targeting enterprise-level healthcare providers and prescribers within its therapeutic specialties.

Name

Solstice Neurosciences

Legal name

USWM, LLC

Website

https://solsticeneuro.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Solstice Neurosciences (DBA US WorldMeds) is a private specialty biopharmaceutical company that develops, licenses, and markets pharmaceutical products for patients with challenging conditions and unmet medical needs in hematology and oncology.

Ownership category

akta.pro rank

Product category

Specialty Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Specialty biopharmaceuticals
• Pharmaceutical manufacturing
• Biopharmaceutical development
• Specialty therapeutics
• Pharmaceutical commercialization

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical product sales: US WorldMeds develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs. Revenue is generated through the sale of specialty pharmaceutical products in hematology and oncology.

Distribution channels1 record

Marketing channels4 records

Core offering

Solstice Neurosciences is a specialty biopharmaceutical company focused on the development, manufacturing, sales, and marketing of specialty biopharmaceutical products. The company targets challenging medical conditions and unmet medical needs, operating as a vertically integrated specialty pharma entity with proprietary product development and commercialization capabilities.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Clinical Trial PartnerscoreStrategic or Co-development PartnerUS WorldMeds partners on clinical trials to bring safe, effective therapies to patients through innovation in rare disease research. The company engages in collaborative research and development efforts to advance therapeutic candidates.
• Research Grant PartnerscoreStrategic or Co-development PartnerUS WorldMeds participates in grant-based research collaborations supporting rare disease research initiatives. The company fuels future breakthroughs through partnerships in clinical trials and grants.

Recent moves4 records

Expansion highlights3 records

Direct peers

• Jazz Pharmaceuticals: Specialty biopharma focused on neuroscience, hematology/oncology, and rare diseases with marketed products and integrated commercial infrastructure — directly comparable therapeutic footprint and patient-population focus.
• Assertio Therapeutics: Specialty pharmaceutical company commercializing differentiated products in neurology and pain — overlapping therapeutic focus and comparable commercial-stage specialty model.
• Recordati Rare Diseases: Specialty pharmaceutical company focused on rare diseases across multiple therapeutic areas including hematology — directly comparable specialty/rare-disease commercial model.
• ANI Pharmaceuticals: Specialty pharma that develops, manufactures, and markets branded and generic prescription pharmaceuticals in niche therapeutic areas — comparable size, integrated model, and specialty focus.
• Supernus Pharmaceuticals: Mid-cap specialty pharma developing and commercializing CNS-focused products with a small commercial organization — similar size, specialty pharma model, and neurology positioning.
• Collegium Pharmaceutical: Specialty pharma with a small commercial team focused on responsible pain management and adjacent specialty indications — similar size and integrated dev-to-commercial structure.
• Aclaris Therapeutics: Smaller specialty pharma developing therapeutics in immunology and rare diseases with limited headcount — comparable business model and niche-indication focus.

Broad incumbents

• Incyte Corporation: Larger specialty biopharma with a strong hematology/oncology franchise (Jakafi) — directly overlapping in stated therapeutic areas but at a far larger scale.
• Alexion (AstraZeneca Rare Disease): Rare-disease-focused biopharma with deep hematology/neurology portfolio (now part of AstraZeneca) — directly comparable rare-disease commercial model, though at vastly greater scale.
• Amneal Pharmaceuticals: Specialty and generics pharma with oncology, neurology, and rare disease franchises — broader scale but overlapping therapeutic and commercial channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/USWorldMeds
• Facebookfacebook.com/USWorldMeds
• LinkedInlinkedin.com/company/usworldmeds

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solstice Neurosciences